Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Infant Bacterial Therapeutics AB (9IB) AI Stock Analysis

4 Followers
DE:9IB

Infant Bacterial Therapeutics AB

(Frankfurt:9IB)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Debt-free balance sheetA debt-free capital structure removes interest expense and reduces refinancing pressure while the company funds clinical development. This provides greater financial flexibility than leveraged peers, although it does not eliminate the need for future financing while programs remain pre-commercial.
Negative Factors
No current product revenueThe absence of revenue means the business has not yet validated a commercial earnings engine and must rely on successful clinical development before recurring sales can begin. This leaves financial performance highly dependent on future regulatory and commercialization outcomes over the next several quarters.

Infant Bacterial Therapeutics AB (9IB) vs. iShares MSCI Germany ETF (EWG)

-20%0%20%40%60%80%100%DE:9IB+50.97%EWG+9.15%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 84.70M
Dividend Yield
―
Average Volume (3M)
510
Price to Earnings (P/E)
-12.0
Beta (1Y)
-0.23
Revenue Growth
―
EPS Growth
16.55%
Country
Germany
Employees
6
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Infant Bacterial Therapeutics AB Business Overview & Revenue Model

Company Description

Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is...

Infant Bacterial Therapeutics AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:9IB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:HNSASE:HNSA53NeutralSEK 4.55B-5.89――68.88%10.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:XBRANESE:XBRANE51NeutralSEK 248.29M-6.47-11.52%―-38.80%-120.18%
SE:IVACCSE:IVACC44NeutralSEK 268.22M-2.63-34.25%―-0.71%54.16%
SE:BINVSE:BINV43NeutralSEK 198.73M-0.39-128.54%―-83.67%-50.29%
SE:EXPRS2SE:EXPRS237UnderperformSEK 39.07M-0.14-104.71%―-2.29%55.71%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:9IBSE:HNSASE:BINVSE:XBRANESE:IVACCSE:EXPRS2Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:9IB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:9IBInfant Bacterial Therapeutics6.251.9043.68%
SE:HNSAHansa Biopharma46.2820.0476.37%
SE:BINVBioInvent International AB2.92-26.98-90.23%
SE:XBRANEXbrane Biopharma AB11.701.6416.30%
SE:IVACCIntervacc AB0.70-0.20-22.21%
SE:EXPRS2ExpreS2ion Biotech Holding AB0.96-5.92-86.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.